The research team, drawing on Optum’s de-identified Clinformatics Data Mart Database covering January 2016 through June 2023, assembled one of the largest cohorts ever used to study this question. Adults with confirmed type 2 diabetes and evidence of chronic kidney disease were divided into two analytical samples. The first included patients who were ineligible for SGLT2 inhibitors—because of kidney failure, dialysis, or repeatedly low filtration rates—or who had shown a suboptimal response to them, a group the investigators describe as having substantial unmet clinical need. The second sample enrolled patients who met criteria mirroring the landmark FLOW trial, excluding anyone with a filtration rate below 25 mL/min/1.73 m² in the preceding six months or evidence of dialysis, transplantation, or kidney failure at baseline.

In the first sample, 16,646 patients initiated once-weekly subcutaneous semaglutide while 33,197 began a sulfonylurea, a dipeptidyl peptidase-4 inhibitor, or a thiazolidinedione—the three oral classes most commonly prescribed when SGLT2 inhibitors are not an option but which current American Diabetes Association guidelines do not prefer. Insulin was deliberately excluded as a comparator because its use typically signals more advanced disease, which would have muddied the statistical waters through confounding by indication. The researchers then tracked four clinical outcomes over time: glycated hemoglobin, estimated glomerular filtration rate, body weight, and systolic blood pressure, using linear mixed-effects models with spline terms for time to capture how benefits evolved across uneven follow-up periods.

The results were striking. By twelve months, patients on semaglutide had achieved model-estimated reductions of 1.18 percentage points in HbA1c, 6.24 kilograms in body weight, and 3.29 mmHg in systolic blood pressure, alongside a 2.75 mL/min/1.73 m² improvement in kidney filtration. The comparator drugs produced smaller gains in HbA1c and filtration rate and essentially no benefit on weight or blood pressure. More alarming for the control group, their modest eGFR improvement reversed entirely at around eighteen months, with kidney function declining below baseline and continuing to fall thereafter. When the two cohorts were compared directly, semaglutide’s advantages at twelve months translated into an additional 0.54 percentage point HbA1c reduction, 6.69 kilograms of extra weight loss, 3.63 mmHg greater blood pressure lowering, and 2.06 mL/min/1.73 m² more improvement in filtration rate, with all differences statistically significant and most benefits persisting beyond two years.

The second analysis addressed the question that matters most to nephrologists: does semaglutide actually keep kidneys from failing? Among 5,873 semaglutide users and 23,649 controls followed for a median of roughly a year, the composite renal outcome—initiation of dialysis, kidney transplantation, two filtration readings below 15 mL/min/1.73 m² at least 28 days apart, or death from any cause—occurred in 1.5 percent of semaglutide patients versus 3.5 percent of controls. Cumulative incidence curves diverged steadily, with rates of 1.1 percent versus 1.9 percent at one year widening to 2.7 percent versus 5.2 percent by four years. After adjusting for demographics, kidney disease stage, baseline filtration rate, comorbidities, and treatment intensity, semaglutide was associated with a 22 percent lower risk of the composite outcome, with a hazard ratio of 0.78 and a confidence interval that just cleared statistical significance.

These findings land with particular force because they replicate, in the messiness of routine care, what the randomized FLOW trial demonstrated under ideal conditions. That phase 3 study, published in 2024, showed a 24 percent reduction in major kidney disease events with once-weekly semaglutide versus placebo, prompting the U.S. Food and Drug Administration to approve the drug for reducing the risk of kidney disease worsening, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease—the only GLP-1 receptor agonist to carry that indication. The new study’s 22 percent risk reduction sits squarely within the 21 to 28 percent range reported in prior comparative analyses of GLP-1 receptor agonists against dipeptidyl peptidase-4 inhibitors and sulfonylureas, suggesting the trial results translate faithfully to the clinic.

The magnitude of the renal protection observed has led researchers to suspect mechanisms beyond the drug’s obvious effects on glucose and weight. Semaglutide mimics the incretin hormone GLP-1, enhancing insulin secretion in a glucose-dependent manner, suppressing glucagon, slowing gastric emptying, and acting on appetite centers in the brain. But its kidney benefits appear to outstrip what improved metabolic control alone would predict, hinting at direct anti-inflammatory and hemodynamic effects within renal tissue—possibly reduced glomerular hyperfiltration, attenuated oxidative stress, and protection of the renal microvasculature. The FLOW trial added another layer of intrigue by showing that semaglutide also reduced heart failure outcomes, underscoring that cardiorenal protection and metabolic control travel together in this drug class.

The study is not without caveats, and the authors are candid about them. As a claims-based analysis, it relied on administrative codes and laboratory values rather than detailed clinical records, so the reasons patients avoided SGLT2 inhibitors—cost, formulary restrictions, clinician preference—could not be fully captured. Residual confounding is an inherent hazard of observational research, and differences in how often the two cohorts had laboratory tests drawn may have biased outcome comparisons. The database covered only commercially insured and Medicare Advantage populations, limiting generalizability to Medicaid beneficiaries and the uninsured. Laboratory data were available for just 30 to 40 percent of individuals, and sicker patients were likely overrepresented because they undergo more frequent monitoring. The on-treatment design also meant follow-up was relatively short for some analyses, with fewer patients contributing data at later time points, which reduces precision around the durability estimates.

Even with those limitations, the clinical implications are considerable. Roughly a quarter of American adults with type 2 diabetes carry a chronic kidney disease diagnosis, and that combination dramatically amplifies cardiovascular risk and mortality. For the substantial minority who cannot take or do not respond to SGLT2 inhibitors, treatment options have historically narrowed to drugs with hypoglycemia risk, weight gain, or limited renal data. The new evidence positions once-weekly semaglutide as a first-line alternative for exactly this population, offering simultaneous improvements in glycemia, weight, blood pressure, and kidney trajectory without increasing hypoglycemia risk. The sustained nature of the benefits—stable HbA1c and weight reductions and preserved filtration advantage through at least two years of follow-up—addresses a persistent worry about whether injectable therapies hold their value in real-world adherence conditions.

The authors call for longer-term studies of hard cardiovascular endpoints and for analyses of how the drug’s comparative effectiveness varies across patient subgroups. But the headline finding is already hard to ignore: in the largest U.S. real-world study of its kind, a drug famous for reshaping the treatment of obesity and diabetes has now shown, outside the trial setting, that it can meaningfully slow the slide toward dialysis, transplantation, and death in one of medicine’s most vulnerable populations. For patients whose kidneys are failing and whose pharmaceutical options have been shrinking, that is not incremental progress—it is a genuine widening of the door.

Subject of Research: Comparative effectiveness of once-weekly semaglutide versus oral glucose-lowering drugs in patients with type 2 diabetes and chronic kidney disease

Article Title: Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease

Article References: Amamoo, J., Wang, Y., Liu, H., Sundar, M., Song, Y., Xie, L., Mehanna, S., Noone, J., Swift, C., & Weir, M. R. (2026). Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease. Advances in Therapy. https://doi.org/10.1007/s12325-026-03744-8

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03744-8

Keywords: semaglutide, type 2 diabetes, chronic kidney disease, GLP-1 receptor agonists, SGLT2 inhibitors, comparative effectiveness, nephrology, kidney outcomes, HbA1c, FLOW trial, real-world evidence, cardiorenal outcomes